Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

by Chan, Arlene, Miles, D., Pivot, X.
Published 2010

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

by Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, Arlene, Pivot, X., Tomczak, P., Provencher, L., Cortes, J., Delmar, P., Scherer, S.
Published 2013

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic brea...

by Miles, D., Chan, Arlene, Dirix, L., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., Harbeck, N., Steger, G., Schneeweiss, A., Wardley, A., Chlistalla, A., Romieu, G.
Published 2010

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breas...

by Gianni, L., Romieu, G., Lichinister, M., Serrano, S., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, Arlene, Lipatov, O., Chan, S., Wardley, A., Greil, R., Moore, N., Prot, S., Pallaud, C., Semiglazov, V.
Published 2013